Ipsen Iqirvo sales reached €78.8M in Q1, driving GENFIT's royalty revenue to €9.6M and triggering early milestone payments.

PharmAla licenses MDMA Candidate ALA-002 to Jupiter Neurosciences for $100M, gaining NCE regulatory designation and U.S. commercialization rights.

Novo Nordisk's Wegovy 7.2 mg CHMP approval delivers 20.7% mean weight loss — rewriting competitive benchmarks for Eli Lilly's...

Tevogen Bio signs letter of intent to evaluate MSO acquisition as part of strategy to reach $100 million in...

GENFIT's Q1 2026 royalties surged 243% as Ipsen's Iqirvo sales reached €78.8M, triggering a $20M milestone payment ahead of...

Humacyte's Symvess gains VA contract covering 170 hospitals, collapsing typical procurement timelines through centralized approval.

Liminatus Pharma InnocsAI $320M stock deal brings IBC101 CAR-T for relapsed/refractory DLBCL into development pipeline.

PharmAla licenses MDMA therapeutic ALA-002 to Jupiter Neurosciences in $100M+ deal featuring novel chemical entity status and FDA exclusivity...

Seer's board has now rejected three unsolicited bids from the Radoff-JEC Group. At $2.40/share, the offer exposes a brutal...

Humacyte's Symvess secures VA Strategic Acquisition Center contract, bypassing hospital-by-hospital approval delays across 170 VA facilities.